

3rd Edition
VACCINE
WORLD ASIA CONGRESS 2021

3rd Annual Vaccine World Asia Congress 2021

17TH - 18TH NOVEMBER 2021
VIRTUAL



Contact Details:
Charmaine Poh
e: charmaine.poh@imapac.com

Elsie Goh Hui Shi
e: elsie.goh@imapac.com

SPECIAL SESSION ON:



LETTER FROM CONFERENCE CHAIRMAN - VWA 2021

Dear Friends and Colleagues,

Welcome to the 3rd Annual Vaccine World Asia Congress 2021! IMAPAC has assembled the 40+ top speakers in our field, and we'll have a great opportunity to share ideas and discuss current trends in the rapidly growing vaccine R&D and manufacturing industry.

It has been more than a year into the pandemic; COVID-19 caught us all unprepared. We are still struggling with a crisis that has taken millions of lives, driven the economies into reverse, and in several countries, negatively impact the healthcare system, etc. With variants, a 4th wave, and slow rollout of vaccination, the picture over the last few months has grown more complex.

At the same time, we see unprecedented efforts in vaccine development and other treatments. Big pharma companies are working together to increase vaccine supply and to develop new vaccines. Experts and scientists across the world worked around the clock to develop vaccines in record time, and the safety, quality and efficacy of COVID-19 vaccines remains a top priority.

We can also see extraordinary and coordinated partnerships between governments, vaccine developers, biopharma, research institutes, logistics companies and multilateral organizations working together in an unprecedented way to ensure that vaccine innovation is accessible to all.

For these reasons, it is my privilege, as the Chair of this conference, to invite you to join us to be a part of the 3rd Annual Vaccine World Asia Congress, live streaming on November 17th - 18th, 2021.

This is a must-attend 2-day virtual conference on vaccine R&D, manufacturing and supply chain management.

It brings together leading international and asian industry experts, from companies and organizations such as: CEPI, IVI, UNICEF, Vaxxinity, Clover Biopharmaceuticals, Osivax, Beijing CC-Pharming, Clinton Health Access Initiative, Yisheng Biopharma, and many more who will be sharing case studies, their latest scientific research, strategies for manufacturing and more.

We strongly encourage you to join us in this discussion and look forward to seeing each and every one of you at the conference.

Come join us virtually at Vaccine World Asia Congress this November! Let's talk and listen together so we can share our knowledge, stimulate the growth of the vaccine industry in Asia and globally and help improve the lives of people worldwide.

Sincerely,



A handwritten signature in blue ink that reads "Jerome H. Kim".

Jerome H. Kim, M.D,
Director- General
International Vaccine Institute (IVI), Seoul, South Korea
Conference Chairman of 3rd Annual Vaccine World Asia Congress 2021

FEATURED SPEAKERS

ADVISORY BOARD MEMBERS



Nikolai Petrovsky,
Professor, Flinders University
and Founder, Chairman
and Chief Scientific Officer,
Vaxine, Australia



Jerome H. Kim, M.D.,
Director General, International
Vaccine Institute, South Korea



Yiwu He, PHD, MBA,
Senior Advisor to the President
and Chief Innovation Officer,
The University of Hong Kong



Keynote Speaker
Zhong Kai Shi, Ph.D.,
Chief Medical Officer, Yisheng
Biopharma, China



Keynote Speaker
Han S Kierstead,
CEO, AIVITA Biomedical, USA



Keynote Speaker
Raches Ella,
Project Lead - SARS-CoV-2
Vaccines, Bharat Biotech,
India



Keynote Speaker
Samir Desai,
President & Head of BU
Biologics, Cadila Healthcare
Limited (Zydus Cadila), India



Keynote Speaker
Mark Newman,
Chief Scientific Officer,
GeoVax, USA



Keynote Speaker
Randall Hyer, MD, PhD, MPH,
Head of Medical Affairs,
Moderna, USA



Keynote Speaker
Joseph Payne,
President & CEO, Arcturus
Therapeutics, USA



Luis Rios-Nogales
MBA, MD, PHD,
Vaccine Key Opinion Leader



Farshad Guirakhoo,
CSO, Vaxxinity, USA



Kiat Ruxrungtham, M.D., Professor
of Medicine, Department
of Medicine Chulalongkorn
University; and Scientific Chair
of the Chula Vaccine Research
Center (ChulaVRC).



Etleva Kadilli,
Director Supply Division,
UNICEF, Denmark



RK Suri,
CEO, DCVMN (Developing
Countries Vaccine
Manufacturers' Network), India



Ingrid Kromann,
Head of CMC, CEPI, UK



Vasan K Sambandamurthy,
CEO, India Alliance, India



Dr. Saurabh Sharma,
Senior Advisor – Immunization,
Clinton Health Access
Initiative, India



Kevin Wang, Ph.D.,
Chairman/CSO, CC-Pharming
Ltd, China



Yujiao Chen,
Co-Founder & Executive VP,
Beijing CC-Pharming Ltd,
China



Alexandre, Le Vert,
CEO, Osivax, France



Nguyen Tuyet Nga,
Vietnam Country Director,
PATH, Vietnam



Matthew Downham, PhD,
Sustainable Manufacturing
Lead, CEPI, UK



Sanjeev Kumar, Ph.D,
DBT/Wellcome Trust India Alliance
Early Career Fellow, ICGEB-Emory
Vaccine Program, International
Centre for Genetic Engineering
and Biotechnology (ICGEB), India



Ajoy Chakrabarti,
Portfolio And Platform
Lead, Bill & Melinda Gates
Foundation, USA



Kirill Dmitriev,
CEO, Russian Direct
Investment Fund, Russia



Lawrence Yap,
Head of Global Technical
Operations, Hilleman Labs,
Singapore



Per Fischer,
CEO, Minervax, Denmark



Ada Wong,
Asia Public Affairs Lead,
Sanofi, Singapore




Dave E. Anderson,
CSO, VBI Vaccines, USA



Frank Malinoski,
CMO, Evelique
Biotechnologies, Austria



Daniel R. Vlock, MD,
CEO, Alopexx, USA



Dr. Gaurab Sircar,
Professor, Visva Bharati
University, Santiniketan, India

Platinum Sponsor



Associate Sponsor



Exhibitors



Advertiser



Supporter



Your Opportunity to Capture Burgeoning Asia Vaccine Market

Your business is about much more than just knocking on doors. Your marketing strategy is much more than a lead generator. To generate sales, you need brand credibility and a genuine leadership position. To generate awareness and response, you need targeted, decision-maker focused, geographically effective marketing. To generate profits, you need marketing service of Vaccine World Asia Congress 2021

Vaccine World Asia Congress 2021 will give you the unique opportunity to position your business in front of decision makers from the World's largest and most innovative companies involved in vaccines manufacturing, R&D, and many more!

In order to get the right audience for you, our internal resources are fully geared towards attracting the largest and most active companies in the vaccines industry in China, Asia and the rest of the world. We also work with a wide range of media partners and industry bodies to guarantee this audience.



For more information contact:

Charmaine Poh

Business Development Manager

T: m: +65 90095208 | p: +65 31090272

Email: charmaine.poh@imapac.com

Why should you sponsor?

Vaccines World Asia Congress 2021 will provide commercial organisations with the opportunity to:

- Educate the market about what you offer.
- Position yourselves as leaders in your field along side key industry figures.
- Raise brand awareness
- Enjoy the option of privately arranged meetings and consultations with selected potential clients.
- Hold face to face meetings with your target profile

Who should sponsor?

World-class solution providers who need to position their products and services in front of decision makers from major vaccine and biologics manufacturers:

- Contract Manufacturing Organisations
- Contract Research Organisations
- Equipment Providers
- Analytical Instrument Manufacturers
- Cell Line Providers
- Cell Culture Facility Providers
- Cell Culture Media Providers
- Technology Platforms
- Automation Systems and Software
- Process Control
- Distribution and Logistics
- Cold Chain Storage
- Packaging

AGENDA AT GLANCE

17th - 18th November 2021, Time in SGT, GMT+8

Day 1 - 17th November 2021		Day 2 - 18th November 2021	
Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Plenary Session: SARS-CoV-2 Vaccine R&D, Manufacturing & Supply Chain Challenges & Opportunities		Vaccines for Emerging Viral Diseases	Ramping Up COVID-19 Vaccine Fill & Finish Capacity
Vaccine CRO/ CDMO Showcase			
Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021	Exhibition Viewing & 1-1 Attendee Networking	
Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Clinical Trial Studies of Next-Gen & New Vaccines	SARS-CoV-2 Vaccine Development Case Studies	New Approaches to Evaluating Vaccine Quality Control & Safety	COVID-19 Vaccine Supply Chain & Logistics Challenges
Vaccine CRO/ CDMO Showcase		Logistics Innovation & Technology Showcase	
Exhibition Viewing & 1-1 Attendee Networking		Exhibition Viewing & 1-1 Attendee Networking	
Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
New System Approaches in Designing Next Generation Vaccines	Effective Strategies to Produce and Manufacture COVID-19 Vaccine at Scale and Pace	Production and Tech Transfers to Speed Up Local Vaccine Production	COVID-19 Vaccine Roll Out & Real Time Monitoring & Temperature Control Management
Platform Tech showcase			
Exhibition Viewing & 1-1 Attendee Networking		Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Whole-Microbe & Genetic Approach of SARS-CoV-2 Vaccine Development		The Way Forward for Vaccine Development and the Challenges Ahead	
End of Conference Day 1		End of Conference Day 2	
Asia Pacific Vaccine Excellence Awards 2021 - Session 1		Asia Pacific Vaccine Excellence Award 2021 - Session 2	



Asia-Pacific Vaccine Excellence Awards (AVEA) 2021 is to recognize the Asian vaccine manufacturer and the achievements it has made over the past year. Despite the COVID-19 pandemic, the industry has overcome adversity and continues with its R&D excellence.

The purpose of AVEA2021 is to recognize the outstanding achievements of vaccine & supply chain experts, organizations, and the newest technologies in Asia. Featuring top vaccine industry leaders, along with the latest advances in technologies and best practices in R&D and manufacturing, the Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.

CONFERENCE DAY 1

17TH NOVEMBER 2021

8.50	IMAPAC's Opening Address	
8.55	Chairman's Opening Address	
	Plenary Session: SARS-CoV-2 Vaccine R&D, Manufacturing & Supply Chain Challenges & Opportunities	
9.00	Leadership Panel Discussion: SARS-CoV-2 Vaccine R&D, Manufacturing & Supply Chain Challenges & Opportunities	
	<ul style="list-style-type: none"> ▶ Industry views of short & long-term effects ▶ Lessons Learnt from the pandemic vaccine development ▶ How vaccine manufacturers working together to combat COVID-19 ▶ The partnership with Big Pharma or international vaccine manufacturers and how it goes 	
	Panelists:	
	1. Randall Hyer , Head of Medical Affairs, Moderna, USA	
	2. Kirill Dmitriev , CEO, Russian Direct Investment Fund, Russia	
	3. Vasan K Sambandamurthy , CEO, India Alliance, India	
10.00	Reserved for Genscript	
10:30	Keynote Presentation: A Deep Dive On mRNA Vaccines	
	Randall Hyer, MD, PhD, MPH , Senior Vice President, Global Medical Affairs, Moderna, USA	
11.00	Addressing Evolving SARS- CoV-2 Variants through a Universal Coronavirus Vaccine	
	Mark Newman , Chief Scientific Officer, GeoVax, USA	
	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
	Clinical Trial Studies of Next- Gen & New Vaccines	SARS-CoV-2 Vaccine Development Case Studies
11.30	Progress Updates of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine	Progress Update of the Vaccine Candidate Development - ZyCoV-D from Zydus Cadila
	Dave Anderson , CSO, VBI Vaccines, USA	Samir Desai , President & Head of BU Biologics, Cadila Healthcare (Zydus Cadila), India
12.00	Novel Vaccines For The Prevention Of Diarrhoeal Diseases	Reserved for PharmaJet
	Frank Malinoski , Chief Medical Officer, Evelique Biotechnologies, Austria	
12.30	Case Study On The Development Of Group B Streptococcal Vaccine For The Prevention Of Adverse Pregnancy Outcomes	UB-612: First Multitope Protein-Peptide Vaccine Against Covid-19, Clinical Status and approaches to Combat Emerging Variants of Concern
	Per Fischer , CEO, Minervax, Denmark	Farshad Guirakhoo , Chief Scientific Officer, Vaxxinity, USA
1.00	Live Attenuated Vaccines in Pertussis	Progress Update of the LUNAR-COV19 Vaccine Development
	Luis Rios-Nogales MBA, MD, PHD , Vaccine Key Opinion Leader	Joseph Payne , President & CEO, Arcturus Therapeutics, USA

1.30	Vaccine CRO/ CMO show-case	
	Exhibition Viewing & 1-1 Attendees Networking	
	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
	New System Approaches in Designing Next Generation Vaccines	Effective Strategies to Produce and Manufacture COVID-19 Vaccine at Scale and Pace
2.00	A New Approach Towards A Universal Influenza Vaccine: Clinical Update Of OVX836 AlexandreLe Vert, CEO, Osivax, France	Covid-19 Vaccine Manufacturing: Dcvmn's Contribution To The Vaccine Manufacturing And Ramp Up Of Capacities Rajinder Suri, CEO, Developing Countries Vaccine Manufacturers Network (DCVMN), India
2.30	Reserved for Aptar Pharma	Adjuvants in Clinical Development of COVID-19 Vaccines Zhong Kai Shi, Chief Medical Officer, Yisheng Biopharma, China
3.00	Next-Generation Epitope Guided Vaccine Design For Allergen Immunotherapy Dr. Gaurab Sircar, Professor, Visva Bharati University, Santiniketan, India	Development And Manufacturing Of Covid19 Vaccines in a Pandemic Situation Ingrid Kromann, Head of CMC, CEPI, UK
3.30	Platform Tech Showcase	
3.30	Exhibition Viewing & 1-1 Attendees Networking	
	Whole-Microbe & Genetic Approach of SARS-CoV-2 Vaccine Development	
4.00	A Fully Personalized COVID-19 Vaccine Made at Point-of-Care Hans S Keirstead, CEO, Aivita Biomedical, USA	
4.30	Progress Update on India's First Indigenous - COVAXIN® Vaccine Development from Bharat Biotech Raches Ella, Project Lead - SARS-CoV-2 Vaccine, Bharat Biotech, India	
5.00	mRNA Vaccine Development in Thailand - Clinical Trials and Manufacturing Prof Kiat Ruxrungham, Professor, Department of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research, Thailand	
5.30	Isolation And Characterization Of Ultrapotent SARS-CoV-2 Neutralizing Human Monoclonal Antibodies Sanjeev Kumar, DBT/Wellcome Trust India Alliance Early Career Fellow, ICGEB-Emory Vaccine Program, International Centre for Genetic Engineering and Biotechnology (ICGEB), India	
6.00	End of Conference Day 1	
6.10	Asia Pacific Vaccine Excellence Award 2021 - Session 1	

CONFERENCE DAY 2

18TH NOVEMBER 2021

8.50	IMAPAC's Opening Address	
8.55	Chairman's Opening Address	
	Vaccine World Asia Congress 2021	Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
	Vaccines for Emerging Viral Diseases	Ramping Up COVID-19 Vaccine Fill & Finish Capacity
9.00	<p>Developing an Intervention Target Product Profile for Vaccine Development targeting SARS-CoV-2 Variants of Concern (VoC)</p> <p>Ajoy Chakrabati, Portfolio And Platform Lead, Bill & Melinda Gates Foundation, USA</p>	<p>Preparing Pandemic Vaccine Capacity for COVID-19</p> <ul style="list-style-type: none"> ▶ Understand the special considerations for fill & finish of COVID-19 vaccine manufacturing ▶ Understand other critical aspects related to vaccine fill & finish operations and the solutions ▶ Case study of scaling up the fill & finish manufacturing facility while maintaining the safety and quality of the vaccine
9.30	Reserved for GenScript	Reserved for Fill & Finish Service Providers
10.00	<p>Current Plant-Derived Vaccine Status for Emerging Coronavirus Outbreak from CC-Pharming</p> <p>Kevin Wang, Chairman/CSO, Beijing CC-Pharming Ltd, China & Yujiao Chen, Co-Founder & Executive VP, Beijing CCPharming Ltd, China</p>	<p>Best Practices of Aseptic/Fill & Finish Manufacturing for COVID-19 Vaccines</p> <ul style="list-style-type: none"> ▶ Discuss the critical manufacturing process, and aseptic fill & finish production of sterile products ▶ Understand the operational requirement of the aseptic production of COVID-19 vaccine ▶ Discuss the global regulatory and compliance requirements and will include the process validation of an aseptic manufacturing operation for COVID-19 vaccine
10.30	<p>Progress Update from Alopexx on the Synthetic Oligosaccharide-Conjugate Vaccine AV0328 - A Novel Broad-Spectrum Vaccine for the Prevention of Serious Bacterial, Fungal and Protozoal Infections</p> <p>Daniel R. Vlock, MD, CEO, Alopexx, USA</p>	<p>Best Practices on Design and Execution for a Vaccine Fill & Finish Facility</p> <ul style="list-style-type: none"> ▶ Understand the challenges on the facility design, process architecture and project execution ▶ Deep dive on the planning timelines ▶ Case studies discussion on the fill & finish facility design


Vaccine World Asia Congress 2021		Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Vaccine Manufacturing Excellence		COVID-19 Vaccine Roll Out: Last Mile Distribution
11.00	Presentation Topic to be confirmed Lawrence Yap , Head of Global Technical Operations, Hilleman Labs, Singapore	Panel Discussion: Overcoming Last-Mile Delivery Challenges for COVID-19 Vaccine <ul style="list-style-type: none"> ▶ Understand the correct methods to handle vaccine when distribute in rural areas to avoid spoilage vaccines ▶ Discuss the correct communication methods to effective distribution ▶ Understand the contingency plans and establish a standard process to remind patients of their appointments, as well as a list of readily available alternative recipients to be contacted Panelists: Etleva Kadilli , Director Supply Division, UNICEF, Denmark
11.30	Reserved for Vaccine Production Technologies Service Providers	
12.00	Establishing Sustainable Manufacturing in Low- and Middle-income Countries Matthew Downham , Sustainable Manufacturing Lead, CEPI, UK	COVID-19 Vaccine Supply Chain & Logistics Challenges Dr Saurabh Sharma MBBS,Dip LSHTM,MSc PHDC , Senior Advisor- Immunization, Clinton Health Access Initiative (CHAI),India
12.30	Logistics Innovation & Technology Showcase	
Exhibition Viewing & 1-1 Attendees Networking		
Vaccine World Asia Congress 2021		Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
Production and Tech Transfers to Speed Up Local Vaccine Production		COVID-19 Vaccine Roll Out & Real Time Monitoring & Temperature Control Management
2.00	Panel Discussion: Emerging Concepts and Technologies in Vaccine Production and Technology Transfer <ul style="list-style-type: none"> ▶ Understand the new vaccine design and how to offer innovative approaches to address existing challenges of vaccine development and technology transfer ▶ Discussion on the emerging technologies in COVID-19 vaccine development & technology transfer ▶ Discuss the latest trends in vaccine production with focus on COVID-19 vaccines 	Real-Time Logistics Monitoring Tech to Address COVID-19 Vaccine Distribution Challenges <ul style="list-style-type: none"> ▶ Ensure vaccine traceability by implementing a supply chain visibility solution ▶ Combat vaccine counterfeiting and enhance safety monitoring by identifying pre-excursion signals, and take immediate action to intervene and prevent any deviations ▶ Case study discussion on accelerating technology adoption to track the cold chain
2.30	Reserved for Vaccine Logistics Service Providers	

3.00	Reserved for Technology/ Service Provider	<p>Tools and Approaches to Ensure Quality of Vaccines throughout the Cold Chain</p> <ul style="list-style-type: none"> ▶ Understand the compliance and temperature excursion management ▶ Strategies to maintain the excellent quality of vaccines throughout the cold chain even in geographical and infrastructure constraint ▶ Case study on using the right approaches to distribute the vaccine in rural areas
Vaccine World Asia Congress 2021		Global COVID-19 Vaccine Manufacturing & Supply Chain Summit 2021
The Way Forward for Vaccine Development and the Challenges Ahead		
3.30	<p>Improving Immunization Registration, Coverage, And Monitoring In Viet Nam – Path’s Digital Immunization Registry (Ir) System</p> <p>Nguyen Tuyet Nga, MD, PhD, Vietnam Country Director, PATH, Vietnam</p>	
4.00	<p>Address The Challenges Hindering Life-Course Immunization</p> <p>Ada Wong, Asia Public Affairs Lead, Sanofi Pasteur, Singapore</p>	
4.30	<p>Closing Panel Discussion: The Way Forward for Vaccine Development and the Challenges Ahead</p> <ul style="list-style-type: none"> ▶ Will the new vaccines be enough to stop the COVID-19 outbreak? ▶ Will vaccines be available to safeguard the most vulnerable members of the human population? ▶ To understand the vaccine safety and efficacy and discuss the future challenges ahead ▶ Will it be possible to overcome financial and political obstacles and make COVID-19 vaccinations affordable to the entire world's population? <p>Panelists: Matthew Downham, Sustainable Manufacturing Lead, CEPI, UK</p>	
5.30	End of Conference Day 2	
5.40	Asia Pacific Vaccine Excellence Award 2021 - Session 2	

Registration Form

	LIMITED SPECIAL EXPIRES 8TH AUGUST	EARLY BIRD EXPIRES 24TH SEPTEMBER	STANDARD RATES
Networking Package 1: 1 PASS + One 1:1 MEETING	SGD 3595	SGD 3795	SGD 3995
Networking Package 2: 1 PASS + THREE 1:1 MEETING	SGD 5095	SGD 5295	SGD 5495
Networking Package 3: 1 PASS + FIVE 1:1 MEETING	SGD 6995	SGD 7195	SGD 7395

- End User Company Profiles:** Asian and International Biopharmas, BIG Pharmas, Academic & Research Institutes, Government/Regulators, and Non-profit Organizations
- Solution Provider Profiles:** Service/Technology Providers, Consulting Companies, CROs, CMOs, Logistics Providers
- INNER CIRCLE:** If you have a written referral from one of our speakers, you are entitled 15% discount off the rate that is applicable to you. To qualify, please ask the speaker to drop us an email rima.karan@imapac.com



17 - 18 November
Virtual Conference

YOUR DETAILS

Name _____
 Job Title _____ Organization _____
 Address _____
 Postcode _____ Country _____
 Tel _____ Fax _____
 Email _____
 Your primary business _____
 Authorising Manager _____ Authorising manager signature _____

By signing and returning this form, you are accepting our terms and conditions.

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay Credit Card Non-credit card and add US\$100 bank handling fee

Online credit card payment:

Please register at: <https://www.eventbrite.com/e/10th-annual-biologics-manufacturing-korea-2021-non-singapore-companies-tickets-132759594521>

Offline credit card payment:

Visa MasterCard American Express

Name on Card _____ Card Number _____
 Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

- Bank transfer: Payment by bank transfer must quote delegate name and conference name. For bank details & swift code, it will be emailed to you as part of the invoice.
- Cheque payment: Crossed cheque payable to IMAPAC Pte Ltd, and mail it in a sealed envelope to **IMAPAC Pte Ltd, 133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535**

4 Easy Ways to Register:

Online

To book online, visit:
 W: https://www.imapac.com/en/business_conferences/biologics-manufacturing-korea-conference/#register

Telephone

To register over the phone, please call us on
+65 8742 7502

Mail

By cheque made payable to:
IMAPAC PTE. LTD.
 Send with this booking form to:
 IMAPAC PTE. LTD.
 133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535

Group Booking

Send your team & save more!

3 delegates **SAVE 10%**

5 delegates **SAVE 20%**

Call +65 3109 0127

TERMS & CONDITIONS:

- Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
- Registration will not be confirmed until full payment has been received.
- Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
- The registration fee includes refreshments, lunches, cocktails and full conference documentation. The conference fee does not include hotel accommodation.
- Staff at the event will request a credit card guarantee for delegates without proof of payment.

CANCELLATION & SUBSTITUTION POLICY:

- Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit note to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
- A substitution from the same organisation can be made at any time in writing at no extra charge.
- If the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.
- Credit notes remain valid for twelve months.

CHANGES TO CONFERENCE & AGENDA:

IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

2022 CALENDAR OF EVENTS

FEBRUARY



2 - 3 February 2022 | Hybrid



2 - 3 February 2022 | Hybrid

MARCH



9 - 10 March 2022 | Hybrid



9 - 10 March 2022 | Hybrid



9 - 10 March 2022 | Hybrid

MAY



11 - 12 May 2022 | Virtual

JUNE



8 - 9 June 2022 | Hybrid



22 - 23 June 2022 | Hybrid



22 - 23 June 2022 | Hybrid

August



17-18 August 2022 | Hybrid

SEPTEMBER



14 - 15 September 2022 | Hybrid

OCTOBER



19-20 October 2022 | Hybrid



19-20 October 2022 | Hybrid

NOVEMBER



10-11 November 2022 | Hybrid



10-11 November 2022 | Hybrid

About IMAPAC

IMAPAC – CREATING BUSINESS CONFERENCES WITH A CAUSE

IMAPAC is a social enterprise based in Singapore that is on an unrelenting mission to make a difference in businesses of today. We believe that businesses are not only meant to do well, but also to do good. We want companies to find business opportunities at our conferences as well as something good to aim for.

IMAPAC's international conferences are where you join other organizations such as governments, NGOs, businesses, academics, and other stakeholders who are standing up collectively to make a difference, to attest to the fact that businesses can and do make a positive impact to the world we live in.



JUST IMAGINE YOUR IMPACT

For every speaker and delegate participating our events, a child from a developing country gets to go to school for an entire year.